商品名：Neomercazole, Vidalta
Antithyroid drug similar to methimazole. It is a pro-drug converted to methimazole after administration. Like methimazole, the action is to serve as substrate for thyroid peroxidase (TPO) and inhibits it and decreases incorporation of iodide into tyrosine molecules. It also inhibits coupling of mono-iodinated and di-iodinated residues to form T4 and T3. Carbimazole has been preferred in some patients because, compared to methimazole, it may have fewer side effects, such as less frequent GI problems. Oral absorption (based on methimazole concentrations) is 88% in cats.
Carbimazole has been used for treating hyperthyroidism, primarily in cats. Carbimazole has been more readily available in Europe, where there is more clinical experience, than in the US. Experience in the US is limited because of lack of availability. Sustained-release formulation in Europe (Vidalta) administered to people as 15 mg once per day, followed by 10-25 mg once daily in people.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
Vidalta 緩釋錠、人用即放錠與調劑品不可自動換算；現行資料也把每日量與每次量混合。未確認 exact product／法域、貓甲亢診斷、TT4、完整血液學、腎肝與共病、與食物時序及個別調整前，封鎖通用計算、處方與飼主調量。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。